SCHEMBL18940540

SCHEMBL18940540

CCC(=NNc1ccccc1)c1cccnc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.53
MAPT P10636 4/20 0.53
ESR2 Q92731 1/20 0.53
KMT2A Q03164 7/20 0.52
GAA P10253 5/20 0.52
HTT P42858 2/20 0.52
MEN1 O00255 3/20 0.48
TDP1 Q9NUW8 3/20 0.48
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2C9 P11712 1/20 0.48
CYP2C19 P33261 1/20 0.48
TP53 P04637 1/20 0.48
KCNK3 O14649 1/20 0.47
PLOD2 O00469 1/20 0.46
KDM4E B2RXH2 3/20 0.46
TAAR1 Q96RJ0 1/20 0.46
NAMPT P43490 1/20 0.44
L3MBTL1 Q9Y468 1/20 0.43
LMNA P02545 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16770470 1.00 ALDH1A1 (0.53) ALDH1A1MAPTESR2KMT2AGAA
SCHEMBL31213370 0.84 MAPT (0.68) ALDH1A1MAPTESR2KMT2AGAA
SCHEMBL2790591 0.83 KDM4E (0.45) ALDH1A1MAPTESR2KMT2AGAA
SCHEMBL7813527 0.83 ALDH1A1 (0.57) ALDH1A1MAPTKMT2AGAAHTT
SCHEMBL7898671 0.81 KMT2A (0.49) ALDH1A1MAPTKMT2AGAAHTT
SCHEMBL9796184 0.81 KDM4E (0.55) ALDH1A1MAPTKMT2AGAAHTT
SCHEMBL9796180 0.81 KDM4E (0.55) ALDH1A1MAPTKMT2AGAAHTT
SCHEMBL6681734 0.80 RAB9A (0.63) ALDH1A1MAPTKMT2AGAAMEN1
SCHEMBL6681732 0.80 RAB9A (0.63) ALDH1A1MAPTKMT2AGAAMEN1
Hydrochloric Acid SCHEMBL10806635 0.79 KDM4E (0.54) ALDH1A1MAPTKMT2AGAAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3074385-B1 PIPERIDINE DERIVATIVES FOR USE IN THE TREATMENT OR PREVENTION OF PSYCHIATRIC AND NEUROLOGICAL CONDITIONS TAKEDA PHARMACEUTICALS CO (JP) 2021-12-22 EP disclosed
US-10562882-B2 Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2020-02-18 US disclosed
US-20170166553-A1 Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166553-A1 Piperidine Derivatives for Use in the Treatment or Prevention of Psychiatric and Neurological Conditions GRIN2C, GRIN2A, PNMT ALDH1A1 220/4885MAPT 199/4885ESR2 1027/4885
US-10562882-B2 Piperidine derivatives for use in the treatment or prevention of psychiatric and neurological conditions GRIN2C, GRIN2A, PNMT ALDH1A1 220/4885MAPT 199/4885ESR2 1027/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.